Drugs / 4SCAR-PSMA T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04429451 | Jun 2026 → Oct 2029 expected | — | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR-PSMA T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04429451 ↗ |
| Action | Deplete | “The CAR molecules enable the T cells to recognize and kill tumor cells or tumor stromal tissues through the recognition of a surface antigen, PSMA.” NCT04429451 ↗ |
| Modality | Cell therapy | “PSMA-specific CAR-T cell therapy” NCT04429451 ↗ |
| Route | Intravenous | “via IV” NCT04429451 ↗ |